Articles Archives - Epsilogen

Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech

This article appeared in Fierce Biotech, March 2 2022

See the article in full here

Epsilogen raises £30.8M series B to support testing IgE antibody against ovarian cancer | BioWorld

Epsilogen Ltd was profiled in BioWorld on March 2, 2022.

See the article in full here

Epsilogen’s CEO speaks to Lu Rahman about their ongoing work in developing novel IgE antibodies to treat cancer.

This article first appeared in Drug Discovery World, Spring 2021, Volume 22, Issue 2.

See the article in full here

BioCentury

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen Ltd was profiled in BioCentury’s Emerging Company Profile on June 5, 2020.

See the article in full here

IGEM Therapeutics: Pursuing Novel IgE Antibodies For Solid Tumors

Emerging Company Profile: IGEM Therapeutics has been spun out of King’s College London to evaluate the use of IgE-based monoclonal antibodies for the treatment of cancer, including difficult-to-reach solid tumors….

…..

See the article in full here: https://scrip.pharmaintelligence.informa.com/SC123214/IGEM-Therapeutics-Pursuing-Novel-IgE-Antibodies-For-Solid-Tumors

Genetic Engineering News Article

Not to be Sneezed At

One of the stand-out technologies discussed by London-based immuno-oncology start-up Epsilogen was in antibody therapeutics…..

See the article in full here: https://www.genengnews.com/gen-exclusives/biotrinity-conference-focuses-on-nextgen-healthcare/77901102